Aurobindo Pharma's subsidiary recalls epilepsy drug in US

US-based unit of drug firm Aurobindo Pharma is voluntarily recalling a lot Gabapentin capsules, an anti-epilepsy drug, in the American market, as some empty capsules were found in certain batches.
"Aurobindo Pharma USA is voluntarily recalling lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count bottles to the consumer level," the company said in a statement.
The product lot has been found to contain some empty capsules, it added.
Empty capsules could result in missed dose of gabapentin resulting in adverse health consequences that could range from no effect, short term reduction in efficacy, short term withdrawal effect, or long period seizures that could be life-threatening, Aurobindo Pharma USA said.

The company said it has not received any reports of adverse events related to this recall to date, but has received four complaints for empty capsules.
Pharma USA, Inc is notifying its distributors and customers by recall letters and is arranging for return of all recalled product," it said.
Consumers, distributors, and retailers that have product which is being recalled should stop using, distributing, or dispensing the affected lot and return to place of purchase, it added.
Aurobindo Pharma shares closed at Rs 1,110.45 apiece on the BSE, down 0.71 per cent from its previous close.